Neuroendocrine dysfunction in patients with mood disorders;Neuroendocrinologia dei disturbi dell'umore

Minerva Psichiatrica

Volumn 47, Issue 1, 2006, Pages 11-24

  Mazza, M ^a   Bria, P ^a   Janiri, L ^a   Mazza, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bipolar depression; HPA axis; Major depression; Mood disorders; Neuroendocrine system

Indexed keywords

BIPOLAR DISORDER; HORMONAL REGULATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; MAJOR DEPRESSION; MOOD DISORDER; NEUROENDOCRINE DISEASE; NEUROMODULATION; PATHOPHYSIOLOGY; REVIEW;

EID: 33644754092     PISSN: 03911772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Rasgon NL. Anatomic, functional, and clinical studies of neuroendocrine function in bipolar disorder. Adv Stud Med 2003;3(8A):S726-32.
2. Kaplan HI, Sadock BJ, Grebb JA. Psichiatria: manuale di scienze del comportamento e psichiatria clinica. 7° ed. Torino: CSI; 1996.
3. Mazza M, Satta MA, Bria P, Mazza S. Neuroendocrinology of mood disorders. Clin Ter 2004;155:537-41.
4. Loosen PT. The TRH-induced TSH response in psychiatric patients: a possible neuroendocrine marker. Psychoneuroendocrinology 1985;10:237-60.
5. Duval F, Macher JP, Mokrani MC. Difference between evening and morning thyrotropin responses to protirelin in major depressive episode. Arch Gen Psychiatry 1990;47:443-8.
6. Kirkegaard C, Faber J, Hummer L, Rogowski P. Increased levels of TRH in cerebrospinal fluid from patients with endogenous depression. Psychoneuroendocrinology 1979;4:227-35.
7. Joffe RT, Singer W, Levitt AJ, MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricydic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993;50:387-93.
8. Siever LJ, Davis KL. Overview: toward a dysregulation hypothesis of depression. Am J Psychiatry 1985;142:1017-31.
9. Trestman RL, Yehuda R, Coccaro E, Horvath T, Knott P, Gabriel S et al. Diurnal neuroendocrine and autonomic function in acute and remitted depressed male patients. Biol Psychiatry 1995;37:448-56.
10. Ehlert U, Gaab J, Heinrichs M. Psychoneuroendocrinological contributions to the etiology of depression, posttraumtic stress disorder, and stress-related bodily disorders: the role of the hypothalamus-pituitary-adrenal axis. Biol Psychol 2001;57:141-52.
11. Burke HM, Davis MC, Otte C, Mohr D. Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinol 2005;30:846-56.
12. Otte C, Hart S, Neylan TC, Marmar CR, Yaffe K, Mohr DC. A meta-analysis of glucocorticoid reactivity in human aging: implications for Alzheimer's disease and depression. Psychoneuroendocrinology 2005;30:80-91.
13. Ferro FM, Janiri L, De Bonis C, Del Carmine R, Tempesta E. Clinical outcome and psychoendocrinological investigations in a case of lethal catatonia. Biol Psychiatry 1991;30:197-200.13.
14. Pozzi G, Janiri L, Ferro FM, Maccallini A, De Bonis C, Maussier ML et al. Is catatonia a separate nosological entity related to affective disorders? Psychopathological observations and biological correlates in seven clinical cases. Eur J Psychiatry 1998;12:32-4.
15. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554-65.
16. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 2005;66:5-13.
17. Holsboer F. The corticosteroid hypothesis of depression. Neuropsychopharmacology 2000;23:477-501.
18. Zobel AW, Nickel T, Sonntag A, Uhr M, Holsboer F, Ising M. Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression: a prospective study. J Psychiatr Res 2001;35:83-94.
19. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
20. O'Connor TM, O'Halloran DJ, Shanahan F. The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia. Q J Med 2000;93:323-33.
21. Della Marca G, Farina B, Mennuni GF, Mazza S, Di Giannantonio M, Spadini V et al. Microstructure of sleep in eating disorders: preliminary results. Eat Weight Disord 2004;9:77-80.21.
22. Gold PW, Goodwin FK, Chrousos GP. Clinical and biochemical manifestations of depression: relationship to the neurobiology of stress. N Engl J Med 1988;319:348-53.
23. Pariante CM, Pearce BD, Pisell TL, Owens MJ, Miller AH. Steroid-independent translocation of the glucocorticoid receptor by the antidepressant desipramine. Mol Pharmacol 1997;52:571-81.
24. Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid resversal of psychotic depression using mifepristone. J Clin Psychopharmacol 2001;21:5l6-21.
25. Young AH. Cortisol in mood disorders. Stress 2004;7:205-8.
26. Holsboer F. Corticotropin-releasing hormone modulators and depression. Curr Opin Investig Drugs 2003;4:46-50.
27. Yuuki M, Ida I, Oshima A, Kumano H, Takahashi K, Fukuda M et al. HPA axis normalization, estimated by DEX/CRH test, but less alteration on cerebral glucose metabolism in depressed patients receiving ECT after medication treatment failures. Acta Psychiatr Scand 2005;112:257-65.
28. Pfennig A, Kunzel HE, Kern N. Hypothalamus-pituitary-adrenal system regulation and suicidal behaviour in depression. Biol Psychiatry 2005;57:336-42.
29. Nemeroff CB, Owens MJ, Bissette G, Andom AC, Stanley M. Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry 1988;45:577-9.
30. Birmaher B, Dahl RE, Perel J. Corticotropin-releasing hormon challenge in prepuberal major depression. Biol Psychiatry 1996;39:267-77.
31. Goodyer IM, Altham PME. Short term outcome of major depression. A high cortisol/DHEA ratio and subsequent disappointing life events predict persistent depression. Psychol Med 1997;28:265-73.
32. Rush AJ, Giles DE, Schlesser MA, Orsulak PJ, Weissenburger JE, Fulton CL et al. Dexamethasone response, thyrotropin releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 1997;41:915-28.
33. Duval F, Mokrani MC, Bailey P, Correa H, Diep TS, Crocq MA et al. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 1999;24:695-712.
34. Mokrani MC, Duval F, Crocq MA, Bailey P, Macher JP. HPA axis dysfunction in depression: correlation with monoamine system abnormalities. Psychoneuroendocrinology 1997;22 Suppl 1:S63-8.
35. Dinan TG. Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatry 1994;164:365-71.
36. Esel E, Kartalci S, Tutus A, Turan T, Sofuoglu S. Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Progr Neuropsychopharmacol Biol Psychiatry 2004;28:303-9.
37. Peteranderl C, Antonijevic IA, Steiger A, Murck H, Held K, Frieboes RM et al. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J Psychiatr Res 2002;36:189-96.
38. Sullivan PF, Wilson DA, Mulder RT, Joyce PR. The hypothalamic-pituitary- thyroid axis in major depression. Acta Psychiatr Scand 1997;95:370-8.
39. Engum A, Bjoro T, Mykletun A, Dahl AA. An association between depression, anxiety and thyroid function: a clinical fact or an artefact? Acta Psychiatr Scand 2002;106:27-34.
40. Demet MM, Ozmen B, Deveci A, Boyvada S, Adiguzel H, Aydemir O. Depression and anxiety in hyperthyroidism. Arch Med Res 2002;33:552-6.
41. Cooke RG, Joffe RT, Levitt AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid patients. J Clin Psychiatry 1992;53:16-8.
42. Sawka AM, Gerstein HC, Marriott MJ. Does a combination regimen of Thyroxine (T4) and 3,5,3′-Triiodothyronine improve depressive symptoms better tha T4 alone in patients with Hypothyroidism? Results of a double-blind, randomised, controlled trial. J Clin Endocrinol Metab 2003;88:4551-5.
43. Degner D, Meller J, Bleich S, Schlautmann V, Ruther E. Affective disorders associated with autoimmune thyroiditis. J Neuropsychiatry Clin Neurosci 2001;13:532-3.
44. Isogawa K, Nagayama H, Tsutsumi T, Kiyota A, Akiyoshi J, Hieda K. Simultaneous use of thyrotropin-releasing hormone test and combined dexamethasone/corticotropine-releasing hormone test for severity evaluation and outcome prediction in patients with major depressive disorder. J Psychiatr Res 2005;39:467-73.
45. Shively CA, Bethea CL. Cognition, mood disorders and sex hormones. ILAR J 2004;45:189-99.
46. Bloch M, Daly RC, Rubinow DR. Endocrine factors in the etiology of postpartum depression. Compr Psychiatry 2003;44:234-46.
47. Steiner M, Dunn E, Born L. Hormones and mood: from menarche to menopause and beyond. J Affective Disorders 2003;74:67-83.
48. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. CNS Drugs 2000;13:286-304.
49. Bao AM, Hestiantoro A, Van Someren EJW, Swaab DF, Zhou JN. Colocalization of corticotropin-releasing hormone and oestrogen receptor-_ in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005;128:1301-13.
50. Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs 2001;15:797-817.
51. Carnahan RM, Perry PJ. Depression in aging men. Drugs Aging 2004:21:361-6.
52. Swaab DF, Bao AM, Lucassen PJ. The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 2005;4:141-94.
53. Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda M, Renner U, Holsboer F et al. Endocrine disturbances in depression. J Endocrinol Invest 2005;28:89-99.
54. Spinelli MG. Neuroendocrine effects on mood. Rev Endocr Metab Disord 2005;6:109-15.
55. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 1993;14:76-122.
56. van Londer L, Goekoop JG, van Kempen GM. Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997;17:284-92.
57. Griebel G, Sirniand J, Serradeil-Le Gal C. Anxiolotic and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002;99:6370-5.
58. Keck ME, Welt T, Muller MB. Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model. Neuropsychopharmacol 2003;28:235-43.
59. Mazza M, Della Marca G, Mennuni GF, Bria P, Mazza S. Sleep disturbances and depression: a review. Minerva Psichiatr 2005;46:175-88.59.
60. Inder WJ, Donald RA, Prickett TCR, Frampton CM, Sullivan PF, Mulder RT et al. Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biol Psychiatry 1997;42:744-7.
61. Zhou JN, Riernersma RF, Unmehopa UA. Alterations in arginine vasopressin neurons in the suprachiasmatic nucleus in depression. Arch Gen Psychiatry 2001;58:655-62.
62. Mazza M, Della Marca G, Paciello N, Mennuni G, Bria P, Mazza S. Orexin, sleep and appetite regulation: a review. Clin Ter 2005;156:93-6.
63. Deuschle M, Blum WF, Englaro P. Palsma leptin in depressed patients and healthy controls. Horm Metab Res 1996;29:714-7.
64. Antonijevic IA, Murck H, Frieboes RM, Horn R, Brabant G, Steiger A. Elevated nocturnal profiles of serum leptin in patients with depression. J Psychiatr Res 1998;32:403-10.
65. Rush AJ, Giles DE, Schlesser MA. Dexametasone response, thyrotropin releasing hormone stimulation, rapid eye movement latency, and subtypes of depression. Biol Psychiatry 1997;41:915-28.
66. Schmider J, Lammers CH, Gotthardt U, Dettling M, Holsboer F, Heuser IJ. Combined dexamethasone/corticotropin-releasing hormone test in acute and remitted manic patients, in acute depression and in normal controls. Biol Psychiatry 1995;38:797-802.
67. Watson S, Gallagher P, Ritchie JC, Ferrier IN, Young AH. Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. Br J Psychiatry 2004;184:496-502.
68. Linkowski P, Brauman H, Mendlewicz J. Thyrotropin response to thyrotropin-releasing hormone in unipolar and bipolar affective illness. J Affect Disord 1981;3:9-16.
69. Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle with deferrence to polycystic ovary syndrome. Jpn J Psychiatry Neurol 1993;47:825-42.
70. Sobczak S, Honig A, van Duinen MA, Riedel WJ. Serotonergic dysregulation in bipolar disorders: a literature review of serotonergic challenge studies. Bipolar Disord 2002;4:347-56.
71. Sassi RB, Nicoletti M, Brambilla P, Harenski K, Mallinger AG, Frank E et al. Decreased pituitary volume in patients with bipolar disorder. Biol Psychiatry 2001;50:271-80.
72. O'Donovan C, Kusumakar V, Graves GR, Bird DC. Menstrual abnormalities in polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-30.
73. Gilmor ML, Skelton KH, Nemeroff CB, Owens MJ. The effects of chronic treatment with the mood stabilizers valproic acid and lithium on corticotropin-releasing factor neuronal systems. J Pharmacol Exp Ther 2003;305:434-9.
74. Isojarvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla W. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-84.
75. Bartalena L, Pellegrini L, Meschi M, Antonangeli L, Bagozzi F, Dell'Osso L et al. Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Res 1990;34:13-7.
76. Kusalic M. Grade II and grade III hypothyroidism in rapid-cycling bipolar patients. Neuropsychobiology 1992;25:177-81.
77. Post RM, Kramlinger KG, Joffe RT, Roy-Byrne PP, Rosoff A, Frye MA et al. Rapid cycling bipolar affective disorder: lack of relation to hypothyroidism. Psychiatry Res 1997;72:1-7.
78. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990;47:435-40.
79. Gyulai L, Bauer M, Bauer MS, Garcia-Espana F, Cnaan A, Wybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry 2003;53:899-905.
80. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry 2001;2:59-69.
81. Cole DP, Thase ME, Mallinger AG, Scares JC, Luther JF, Kupfer DJ et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry 2002;159:116-21.
82. Cervantes P, Gelber S, Kin F, Nair VNP, Schwartz G. Circadian secretion of cortisol in bipolar disorder. J Psychiatry Neurosci 2001;26:411-6.
83. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr Clin North Am 2005;28:469-80.
84. Rasgon NL, Harden CL. Neuroendocrine dysfunction in women with epilepsy or bipolar disorder: implications for patient management. Adv Stud Med 2003;3(8A): S740-4.
85. Marangell LB. Thyroid hormones and mood: are population data applicable to clinical cohorts? Acta Psychiatr Scandin 2002;106:1-2.